Relapsed Or Refractory Chronic Lymphocytic Leukemia clinical trials

Explore recruiting relapsed or refractory chronic lymphocytic leukemia clinical trials.

Recruiting relapsed or refractory chronic lymphocytic leukemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Or Refractory Chronic Lymphocytic Leukemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multi-Center, Open Label, Uncontrolled, Phase 2a Clinical Trial Evaluating the Safety and Efficacy of the Addition of Ibrutinib to Venetoclax through a MRD-guided Approach in Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia (CLL) IMPROVE (Ibrutinib treatment based on MRD-guided apPROach combined with VEnetoclax)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator’s Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia

Croatia, Poland, Hungary, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Italy, Spain, Germany, France, Poland

Human Pharmacology (Phase I)- Other EU CTIS Study details

HOVON 141 CLL: A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations.

Sweden, Netherlands, Belgium, Norway, Finland, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase I/II study to evaluate the feasibility, safety and preliminary efficacy of point-of-care manufactured anti-CD19 CAR T in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Spain, Belgium, Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Relapsed Or Refractory Chronic Lymphocytic Leukemia trials by city

Relapsed Or Refractory Chronic Lymphocytic Leukemia in Toronto Relapsed Or Refractory Chronic Lymphocytic Leukemia in Vancouver Relapsed Or Refractory Chronic Lymphocytic Leukemia in Montreal Relapsed Or Refractory Chronic Lymphocytic Leukemia in Calgary Relapsed Or Refractory Chronic Lymphocytic Leukemia in Edmonton Relapsed Or Refractory Chronic Lymphocytic Leukemia in Ottawa Relapsed Or Refractory Chronic Lymphocytic Leukemia in Winnipeg Relapsed Or Refractory Chronic Lymphocytic Leukemia in Quebec City Relapsed Or Refractory Chronic Lymphocytic Leukemia in Hamilton Relapsed Or Refractory Chronic Lymphocytic Leukemia in Kitchener Relapsed Or Refractory Chronic Lymphocytic Leukemia in London Relapsed Or Refractory Chronic Lymphocytic Leukemia in Halifax Relapsed Or Refractory Chronic Lymphocytic Leukemia in New York Relapsed Or Refractory Chronic Lymphocytic Leukemia in Los Angeles Relapsed Or Refractory Chronic Lymphocytic Leukemia in Chicago Relapsed Or Refractory Chronic Lymphocytic Leukemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease